Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Eli Lilly and Company

29 shared events · Importance 9 · Last updated Sep 24, 2026

Importance
9
Shared Events
29
Actions
3
Sentiment
0.5128776445321725
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
95
Regulatory
United States — Food and Drug Administration: The FDA granted clearance to the Elecsys pTau217 blood test, a regulatory action that enables U.S. marketing and use of the test.
Eli Lilly and Company: Eli Lilly partnered with Roche in developing the test and will benefit from royalties or shared revenue, strengthening its presence in Alzheimer's diagnostics.
Aug 24, 2026 · 7 articles
89
Regulatory
United States — Food and Drug Administration: The FDA has stated that unapproved retatrutide sales are illegal and cannot be compounded. Lilly has referred over 200 entities to the FDA and delayed its submission to Q1 2027, making the agency central to the regulatory environment.
Eli Lilly and Company: Eli Lilly is the plaintiff, filing six lawsuits and escalating its campaign against unauthorized sellers of retatrutide. The company also delayed its FDA submission to Q1 2027 and allowed limited early access, reflecting both legal and regulatory actions that protect its pipeline and market position.
Aug 12, 2026 · 6 articles
82
Regulatory
United States — Food and Drug Administration: The FDA granted full approval to the Inluriyo and Abemaciclib combination, enabling U.S. commercialization of the regimen.
Eli Lilly and Company: Eli Lilly receives FDA full approval for Inluriyo plus Abemaciclib, expanding its oncology franchise and adding a new revenue stream. The approval strengthens its competitive position in breast cancer treatment.
Sep 18, 2026 · 6 articles
73
Regulatory
United States — Food and Drug Administration: US regulator that has not added a NAION warning to GLP-1 labels but is conducting an ongoing review through its Sentinel Initiative. Its eventual decision could reshape labeling and prescribing for the entire drug class.
Eli Lilly and Company: Co-defendant in the NAION litigation involving Mounjaro, Zepbound and Trulicity. It says patient safety is its top priority and that it monitors safety reports, but the lawsuits create legal and reputational exposure for its GLP-1 portfolio.
Sep 21, 2026 · 20 articles
71
Business
United States — Food and Drug Administration: Approved Tirzepatide for cardiovascular risk reduction; regulatory decisions on Retatrutide and Orforglipron are key catalysts.
Eli Lilly and Company: Central company; reported record revenue, raised guidance, and saw stock surge. Multiple acquisitions and pipeline progress bolster growth outlook.
Aug 23, 2026 · 6 articles
65
Regulatory
United States — Food and Drug Administration: The FDA has been cracking down on compounded GLP-1s; the study supports the need for further regulatory action.
Eli Lilly and Company: Eli Lilly's Zepbound is another GLP-1 drug involved; the study could prompt regulatory actions that impact its distribution.
Jul 07, 2026 · 6 articles
60
Tech
United States — Food and Drug Administration: Its Adverse Event Reporting System supplied 13 of the 15 cases reviewed, placing the agency at the center of any potential label or safety review of GLP-1 medications.
Eli Lilly and Company: Maker of tirzepatide-based Mounjaro and Zepbound, which accounted for six of the reported cases. The association adds a safety concern to its fast-growing GLP-1 franchise, a potential headwind for sentiment.
Sep 11, 2026 · 6 articles
60
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> granted Fast Track designation to VERVE-102, indicating its recognition of the therapy's potential to address an unmet medical need.
Eli Lilly and Company: As the parent company of Verve PCSK9-inhibitor gene therapy>>>, Eli Lilly and Company>>> is a key developer of VERVE-102, a gene-editing therapy that has shown promising results in lowering cholesterol. This breakthrough could significantly impact its future market position in cardiovascular medicine.
May 26, 2026 · 12 articles
55
Business
United States — Food and Drug Administration: The FDA cleared the IND for CBL-0201WR, enabling the Phase 2 trial. Its regulatory decisions are critical for the drug's development, but the FDA itself is not directly impacted financially.
Eli Lilly and Company: Eli Lilly's tirzepatide is being combined with CBL-514 in the Phase 2 trial. This collaboration could expand the use of its GLP-1 drug into post-weight management, potentially increasing its market share in the obesity treatment market.
Jul 20, 2026 · 7 articles
53
Domestic
United States — Food and Drug Administration: The United States — Food and Drug Administration approved Eli Lilly and Company's weight loss pill, Foundayo, impacting the pharmaceutical market.
Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
47
Tech
United States — Food and Drug Administration: The agency approved semaglutide for adolescents aged 12 to 17, and the study's findings may inform future labeling or monitoring guidance.
Eli Lilly and Company: As maker of tirzepatide (Mounjaro, Zepbound) and dulaglutide (Trulicity), the company could see increased scrutiny over pediatric use and monitoring requirements.
Sep 21, 2026 · 7 articles
45
Business
United States — Food and Drug Administration: The FDA granted Breakthrough Therapy Designation to BPL-003 and announced regulatory actions to support psychedelic drug development, facilitating the path to market.
Eli Lilly and Company: Eli Lilly is the acquirer, paying $2.8B upfront for Atai Life Sciences to bolster its neuroscience pipeline and diversify beyond its weight-loss drug franchise. The deal is part of a broader acquisition spree funded by strong commercial performance.
Jul 16, 2026 · 25 articles
45
Business
United States — Food and Drug Administration: Approved the tirzepatide label expansion into cardiovascular risk on August 28, 2026, and its pending review of retatrutide is a key 2027 catalyst for Lilly.
Eli Lilly and Company: Central subject of the event: shares fell about 7-8% over the month on pricing and IPR&D charges despite strong Q2 beats and raised 2026 guidance. Citi's Street-high $1,600 target frames the selloff as overdone, leaving the stock as the widest analyst-implied upside in its pharma peer group.
Sep 14, 2026 · 6 articles
45
Business
United States — Food and Drug Administration: Approved Foundayo in April 2026 for weight management, enabling Lilly to manufacture and market the drug in the U.S.
Eli Lilly and Company: Eli Lilly is the primary actor, investing $6.5 billion to expand manufacturing capacity for Foundayo and other medicines, strengthening its supply chain and market position.
Sep 21, 2026 · 7 articles
40
Business
United States — Food and Drug Administration: The Taiwan FDA granted marketing approval for QUVIVIQ, a regulatory milestone that enables commercialization in Taiwan.
Eli Lilly and Company: Eli Lilly completed its acquisition of KC Pharmaceuticals, strengthening its sleep disorder portfolio. Nxera retains rights to future milestone and royalty payments from the orexin programs, benefiting Lilly's pipeline.
Aug 07, 2026 · 6 articles
32
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration previously approved a biologic incorporating Hanmi Pharm. Co., Ltd.'s LAPSCOVERY platform, indicating a regulatory pathway for similar drugs.
Eli Lilly and Company: Eli Lilly and Company obtained exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize sonefpeglutide, expanding its pipeline in areas like short bowel syndrome and other indications, potentially leading to new revenue streams.
Jun 01, 2026 · 11 articles
26
Tech
United States — Food and Drug Administration: Its 2026 removal of boxed warnings from hormone therapy products is cited as context; the study may reinforce the regulatory shift.
Eli Lilly and Company: Lead author Ziyuan Wang now works in pharmacoepidemiology at Eli Lilly, a minor disclosure link to the study.
Sep 08, 2026 · 9 articles
24
Regulatory
United States — Food and Drug Administration: The FDA's roadmap favoring non-animal testing methods is mentioned as a potential growth driver for VivoSim's business.
Eli Lilly and Company: Eli Lilly made a $5.0 million milestone payment to VivoSim related to the FXR program sale, a routine contractual obligation.
Aug 06, 2026 · 6 articles
23
Business
United States — Food and Drug Administration: Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Eli Lilly and Company: Cited among big pharma buyers of radiopharmaceutical assets from 2023 to 2025, reflecting the sector consolidation backdrop to this deal.
Sep 21, 2026 · 6 articles
20
Regulatory
United States — Food and Drug Administration: The FDA's regulatory decisions are the subject of some of Kalshi's new contracts.
Eli Lilly and Company: Eli Lilly is mentioned as the former employer of Alpheus Bingham, who helped build an internal prediction market.
Jul 16, 2026 · 7 articles
17
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration has cleared the CareMiBrain system for use and has approved new monoclonal antibody treatments for Alzheimer's Disease, creating a market for the PET scans.
Eli Lilly and Company: Eli Lilly and Company developed Kisunla, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
17
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration granted Orphan Drug Designation to Rentosertib for IPF in February 2023, a regulatory milestone that supports the drug's development. The current event does not involve new FDA action.
Eli Lilly and Company: Eli Lilly and Company is mentioned as one of Insilico's collaboration partners, contributing to Insilico's contract value and revenue growth. The event has minimal direct impact on Eli Lilly.
Sep 10, 2026 · 6 articles
15
Business
United States — Food and Drug Administration: The FDA declined to approve Lantheus' LNTH-2501 application due to manufacturing issues, a setback for Lantheus' pipeline.
Eli Lilly and Company: Eli Lilly is mentioned as a prior acquirer of Point Biopharma and as a former partner with Lantheus on a PSMA-directed therapeutic that was abandoned after an unfavorable trial.
Aug 03, 2026 · 7 articles
14
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration has granted various designations to MiNK Therapeutics' programs and is involved in the approval pathway for its Fabry gene therapy.
Eli Lilly and Company: Eli Lilly and Company has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
0
Business
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
0
Regulatory
Dec 22, 2025 · 23 articles
0
Regulatory
Feb 07, 2026 · 6 articles
0
Business
Apr 01, 2026 · 7 articles
0
International
Apr 01, 2026 · 16 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.